Abstract
Background Progressive deterioration of synaptic plasticity and synaptic connectivity between neurons is a neurophysiological hallmark of brain ageing and has been linked to the severity of dementia. We hypothesized that if synaptic disconnection as the neuropathology of Alzheimer’s disease (AD) is responsible for the failure of the brain to integrate various regions into effective networks, then electroencephalographic evidence of the disruption of functional connectivity might be used to diagnose Alzheimer’s dementia. We proposed that changes in EEG coherence, a measure of functional interaction between the brain collaborating areas, can be detected in a clinical setting and serve as a marker of neuronal disconnection. Improving the accuracy and reducing the time needed to diagnose AD could allow timely interventions, treatments, and care cost reduction.
Methods This study examined group differences in EEG coherence within global cortical networks at rest and during executive challenges among patients with AD, individuals with mild cognitive impairment, and healthy controls.
Results Decreased EEG coherence has been discovered in cross-hemisphere frontal, temporal, parietal and occipital pairs in the AD group at rest and when challenged with tasks requiring comprehension, analysis, perceptual-motor response, and executive functioning. The most notable changes were detected in F3-F4 Beta with the visual-spatial task challenge, P7-P8 Beta during the writing task, T7-T8 Gamma during a task requiring speech understanding and O1-O2 Alpha during orientation in space task.
Conclusions The study identified several potential EEG biomarkers of AD. More research is needed to identify sensitivity and specificity of the markers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Office of the University of Alberta, Canada, reviewed and gave ethical approval for this work(HREBA.CHC-16-0053)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Tel: +1(403)258-0040
Tel: +1604)822-2211
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos